Sabrin Tahri

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.

Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.

Journal: Blood
Published: May 29, 2025

Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.

Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.

Journal: Blood
Published: May 29, 2025

The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy.

The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy.

Journal: Blood
Published: August 08, 2024

Interferon gamma-mediated prevention of tumor progression in a mouse model of multiple myeloma.

Interferon gamma-mediated prevention of tumor progression in a mouse model of multiple myeloma.

Journal: HemaSphere
Published: December 08, 2023

Clinical Outcomes and Evolution of Clonal Hematopoiesis in Patients with Newly Diagnosed Multiple Myeloma.

Clinical Outcomes and Evolution of Clonal Hematopoiesis in Patients with Newly Diagnosed Multiple Myeloma.

Journal: Cancer research communications
Published: August 09, 2023

Inhibition of MICA and MICB shedding enhances memory-like NK-cell-mediated cytotoxicity against multiple myeloma.

Inhibition of MICA and MICB shedding enhances memory-like NK-cell-mediated cytotoxicity against multiple myeloma.

Journal: Blood advances
Published: June 01, 2023

An IL-1β-driven neutrophil-stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma.

An IL-1β-driven neutrophil-stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma.

Journal: Nature immunology
Published: March 24, 2023

Extreme body mass index and survival in newly diagnosed multiple myeloma patients.

Extreme body mass index and survival in newly diagnosed multiple myeloma patients.

Journal: Blood cancer journal
Published: September 18, 2022

Single-cell multi-omics of human clonal hematopoiesis reveals that DNMT3A R882 mutations perturb early progenitor states through selective hypomethylation.

Single-cell multi-omics of human clonal hematopoiesis reveals that DNMT3A R882 mutations perturb early progenitor states through selective hypomethylation.

Journal: Nature genetics
Published: January 06, 2022

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.

Journal: Cancer cell
Published: June 26, 2021

Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia.

Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia.

Journal: Blood advances
Published: April 05, 2021

The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape.

The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape.

Journal: Nature immunology
Published: June 25, 2020
Showing 1-12 of 19

Last Updated: 09/26/2026